EX-10.310-Q·CIK 1826892·0001193125-26-462306

Promissory Note

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 09:01 EST

Exhibit 10.3

THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

PROMISSORY NOTE

$400,000.00

November 10, 2026
San Diego, California, United States

For value received, BioAtla, Inc., a Delaware corporation (the “Company”), promises to pay to Inversagen AI LLC (the “Holder”), the principal sum of four hundred thousand dollars ($400,000.00). Interest shall accrue from the date of this Promissory Note (this “Note”) on the unpaid principal amount at a rate equal to 10% per annum, computed as simple interest on the basis of a 365-day year. This Note and any equity securities issuable upon conversion thereof are collectively referred to herein as the “Securities.” This Note is subject to the following terms and conditions:

1.

Basic Terms.

(a)

Maturity.Principal and any accrued but unpaid interest under this Note shall be due and payable upon demand of the Holder at any time after November 10, 2027 (the “Maturity Date”). Interest shall accrue on this Note and shall be due and payable with each installment of principal. Notwithstanding the foregoing, the entire unpaid principal sum of this Note, together with accrued and unpaid interest thereon, shall become immediately due and payable upon the commission of any act of bankruptcy by the Company, the execution by the Company of a general assignment for the benefit of creditors, the filing by or against the Company of a petition in bankruptcy or any petition for relief under the federal bankruptcy act or the continuation of such petition without dismissal for a period of 90 days or more, or the appointment of a receiver or trustee to take possession of the property or assets of the Company.

(b)

Payment; Prepayment.All payments shall be made in lawful money of the United States of America at such place as the Holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to the accrued interest then due and payable, and the remainder shall be applied to principal. The Company may prepay this Note at any time without penalty with the written consent of the Holder; provided however, that this Note shall not be prepaid before December 19, 2026.


2.

Optional Conversion of Accrued Interest Upon Maturity or Prepayment. At the Maturity Date or upon the prepayment of all or a portion of the principal then outstanding, any accrued but unpaid interest with respect to the principal amount being repaid or maturing (the “Conversion Amount”) shall, at the option of the Holder, be paid in cash or converted into a number shares of the Company’s Common Stock, par value $0.0001 per share (the “Conversion Shares”) equal to the Conversion Amount divided by the Conversion Price. For purposes of this Note, the “Conversion Price” means the volume-weighted average price of the Conversion Shares on the primary exchange where the stock is traded for the five (5) consecutive trading day period beginning on December 14, 2026 and ending on and including December 18, 2026 (the “Valuation Period”). In the event of a prepayment of a portion of the principal amount of this Note, the amount of accrued interest eligible for conversion shall be calculated with respect to the portion of the principal being prepaid as of the date of such prepayment. Upon any such conversion, the Company shall as soon as practicably possible (and in any event within two (2) business days following the Maturity Date or prepayment date), issue and deliver to the Holder a certificate or electronic book-entry statement representing the applicable number of Conversion Shares. No fractional shares will be issued; any fractional share resulting from the calculation shall be rounded down to the nearest whole share. Upon conversion of any Conversion Amount, the Company will be forever released from all of its obligations and liabilities under this Note with regard to that accrued interest being converted including without limitation the obligation to pay such accrued interest.

3.

Standstill and Trading Restrictions.

(a)

Trading Standstill. The Holder hereby agrees that, during the period commencing five (5) trading days prior to the first day of the Valuation Period and ending at 4:00 p.m. Eastern Time on the final day of such Valuation Period (the “Standstill Period”), neither the Holder nor any of its affiliates, agents, or entities controlled by or under common control with the Holder (collectively, “Affiliated Entities”) shall, directly or indirectly, engage in any transaction involving the Company’s Common Stock or any instruments or derivative securities linked to or exchangeable for the Company’s Common Stock.

(b)

Prohibited Activities. For the avoidance of doubt, the restrictions in subsection (a) shall strictly prohibit the Holder and its Affiliated Entities from:

(i)

Purchasing or Bidding: Establishing, bidding for, or executing any long position or purchasing shares of common stock on the open market.

(ii)

Short Sales: Engaging in any "short sale" (as defined in Rule 200 of Regulation SHO) or establishing any "naked" or covered short position.

(iii)

Hedging Transactions: Buying, selling, or trading any options, puts, calls, straddles, or entry into any equity swap or other derivative transaction that hedges or transfers the economic risk of ownership of the common stock.

(c)

Acknowledgment of Affiliate Status. The Holder acknowledges that its trading restrictions during the Standstill Period are intended, in part, to prevent market manipulation, maintain an orderly market, and ensure compliance with Rule 102 of Regulation

-2-


M and Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any breach of this Section by the Holder shall entitle the Company to, among other remedies, void the applicable interest conversion election.

4.

Change of Control.In the event of a Change of Control (as defined below) prior to repayment or conversion in full of this Note, immediately prior to such Change of Control, the outstanding principal and any accrued but unpaid interest on this Note shall become immediately due and payable. The term “Change of Control” means (i) a sale of all or substantially all of the Company’s assets other than to an Excluded Entity (as defined below), (ii) a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, limited liability company or other entity other than an Excluded Entity, or (iii) the consummation of a transaction, or series of related transactions, in which any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of all of the Company’s then outstanding voting securities. Notwithstanding the foregoing, a transaction shall not constitute a Change of Control if its purpose is to (A) change the jurisdiction of the Company’s incorporation, (B) create a holding company that will be owned in substantially the same proportions by the persons who hold the Company’s securities immediately before such transaction, or (C) obtain funding for the Company in a financing that is approved by the Company’s Board of Directors. An “Excluded Entity” means a corporation or other entity of which the holders of voting capital stock of the Company outstanding immediately prior to such transaction are the direct or indirect holders of voting securities representing at least a majority of the votes entitled to be cast by all of such corporation’s or other entity’s voting securities outstanding immediately after such transaction.

5.

Stockholders, Officers and Directors Not Liable.In no event shall any stockholder, officer or director of the Company be liable for any amounts due or payable pursuant to this Note.

6.

Interest Rate Limitation.Notwithstanding anything to the contrary contained in this Note, the interest paid or agreed to be paid under this Note shall not exceed the maximum rate of non-usurious interest permitted by applicable law (the “Maximum Rate”). If the Holder shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal remaining owed under this Note or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest contracted for, charged, or received by the Holder exceeds the Maximum Rate, the Holder may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of this Note.

7.

Action to Collect on Note.If action is instituted to collect on this Note, the Company promises to pay all of the Holder’s costs and expenses, including reasonable attorney’s fees, incurred in connection with such action.

8.

Loss of Note.Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note or any Note exchanged for it, and indemnity

-3-


satisfactory to the Company (in case of loss, theft or destruction) or surrender and cancellation of such Note (in the case of mutilation), the Company will make and deliver in lieu of such Note a new Note of like tenor.

9.

Miscellaneous.

(a)

Governing Law.The validity, interpretation, construction and performance of this Note, and all acts and transactions pursuant hereto and the rights and obligations of the Company and Holder shall be governed, construed and interpreted in accordance with the laws of the state of California, without giving effect to principles of conflicts of law.

(b)

Entire Agreement.This Note constitutes the entire agreement and understanding between the Company and the Holder relating to the subject matter herein and supersedes all prior or contemporaneous discussions, understandings and agreements, whether oral or written between them relating to the subject matter hereof.

(c)

Amendments and Waivers.Any term of this Note may be amended only with the written consent of the Company and the Holder. Any amendment or waiver effected in accordance with this Section 7(c) shall be binding upon the Company, the Holder and each transferee of this Note.

(d)

Successors and Assigns.The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective successors and assigns of the Company and the Holder. Notwithstanding the foregoing, the Holder may not assign, pledge, or otherwise transfer this Note without the prior written consent of the Company. Subject to the preceding sentence, this Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, a new note for the same principal amount and interest will be issued to, and registered in the name of, the transferee. Interest and principal are payable only to the registered holder of this Note.

(e)

Notices.Any notice, demand or request required or permitted to be given under this Note shall be in writing and shall be deemed sufficient when delivered personally or by overnight courier or sent by email, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature page, at the most recent address set forth in the Company’s books and records.

(f)

Counterparts. This Note may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and all of which together shall constitute one and the same instrument.

[Signature Page Follows]

-4-


Exhibit 10.3

IN WITNESS WHEREOF, the Company has executed this Promissory Note as of the date first set forth above.

the company:

BioAtla, Inc.

By: /s/ Jay M. Short

(Signature)

Name: Jay M. Short

Title: Chief Executive Officer

Address:
11085 Torreyana Road
San Diego, CA 92121
United States
Email: jshort@bioatla.com

AGREED TO AND ACCEPTED:

The holder:

INVERSAGEN AI LLC

By:/s/ Gene O’Bryan
(Signature)

Name: Gene O'Bryan
Title: Managing Member

Address:
11085 Torreyana Road
San Diego, CA 92121
Email: gene@inversagen.ai


Back to all agreements